Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera

被引：0
|
作者：
Joan How
Gabriela Hobbs
机构：
[1] Massachusetts General Hospital,Department of Medical Oncology
[2] Harvard Medical School,Division of Hematology, Department of Medicine
[3] Brigham and Women’s Hospital,Department of Medical Oncology, Dana
[4] Harvard Medical School,Farber Cancer Institute
[5] Harvard Medical School,undefined
来源：
Current Hematologic Malignancy Reports | 2021年 / 16卷
关键词：
Essential thrombocythemia; Polycythemia vera; Low-risk; Myeloproliferative neoplasm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：473 / 482
页数：9
相关论文
共 50 条
  • [31] Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
    Krecak, Ivan
    Lucijanic, Marko
    Verstovsek, Srdan
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (05) : 155 - 169
  • [32] Expertise-based management in essential thrombocythemia and polycythemia vera
    Finazzi, Guido
    Barbui, Tiziano
    [J]. CANCER JOURNAL, 2007, 13 (06): : 372 - 376
  • [33] Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia
    Alessandro M. Vannucchi
    [J]. Internal and Emergency Medicine, 2010, 5 : 177 - 184
  • [34] Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
    Accurso, Vincenzo
    Santoro, Marco
    Mancuso, Salvatrice
    Contrino, Angelo Davide
    Casimiro, Paolo
    Sardo, Mariano
    Raso, Simona
    Di Piazza, Florinda
    Perez, Alessandro
    Bono, Marco
    Russo, Antonio
    Siragusa, Sergio
    [J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [35] Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk
    Barbui, Tiziano
    Finazzi, Guido
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (04): : 321 - 329
  • [36] Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
    Ivan Krecak
    Marko Lucijanic
    Srdan Verstovsek
    [J]. Current Hematologic Malignancy Reports, 2022, 17 : 155 - 169
  • [37] Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
    Tefferi, Ayalew
    Barbui, Tiziano
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 95 - 108
  • [38] Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
    Tefferi, Ayalew
    Barbui, Tiziano
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1599 - 1613
  • [39] Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
    Tefferi, Ayalew
    Barbui, Tiziano
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : 133 - 143
  • [40] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    [J]. LEUKEMIA RESEARCH, 2018, 69 : 100 - 102
12345